INT173236

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 1.64
Pain Relevance 2.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Sstr2) plasma membrane (Sstr2) cytoplasm (Sstr2)
signal transducer activity (Sstr2)
Anatomy Link Frequency
superior 2
Sertoli cells 1
Sstr2 (Mus musculus)
Pain Link Frequency Relevance Heat
Somatostatin 321 99.98 Very High Very High Very High
dexamethasone 4 97.28 Very High Very High Very High
agonist 45 94.76 High High
Dopamine 11 56.36 Quite High
antagonist 12 5.00 Very Low Very Low Very Low
tolerance 11 5.00 Very Low Very Low Very Low
imagery 10 5.00 Very Low Very Low Very Low
abdominal pain 6 5.00 Very Low Very Low Very Low
anesthesia 5 5.00 Very Low Very Low Very Low
cytokine 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Apoptosis 3 99.92 Very High Very High Very High
Adenoma 25 95.60 Very High Very High Very High
Cancer 64 92.32 High High
Acth-secreting Pituitary Adenoma 14 92.16 High High
Acromegaly 76 91.56 High High
Peripheral Arterial Disease 5 68.16 Quite High
Pituitary Acth Hypersecretion 6 50.00 Quite Low
Coronary Heart Disease 6 46.76 Quite Low
Pituitary Cancer 17 45.16 Quite Low
Leukemia 5 44.92 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Apoptosis is associated with SSTR3 and possibly also with SSTR2 signaling (Danilla et al 2001; Bevan 2005).
SSTR2 Binding (associated) of associated with apoptosis
1) Confidence 0.25 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0.71 Pain Relevance 0.12
In fact, octreotide (that binds preferentially sst2 but only modestly sst5), but not pasireotide (a universal ligand with high binding affinity for sst1, sst2, sst3, and sst5), lost most of its ACTH-inhibiting potential with glucocorticoid pretreatment53 or in patients with CD in vivo.54 Two studies55,56 investigated the effects of SS analogs in human corticotroph adenoma tissues; a superior ACTH inhibition by pasireotide as compared with octreotide55 and a dissociation in some adenomas between the antisecretory and antiproliferative effects of pasireotide56 were reported similar to what is observed in acromegaly.57,58

Efficacy in clinical studies

sst2 Binding (binds) of in superior associated with adenoma, acromegaly, acth-secreting pituitary adenoma and somatostatin
2) Confidence 0.17 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.31 Pain Relevance 0.61
In fact, octreotide (that binds preferentially sst2 but only modestly sst5), but not pasireotide (a universal ligand with high binding affinity for sst1, sst2, sst3, and sst5), lost most of its ACTH-inhibiting potential with glucocorticoid pretreatment53 or in patients with CD in vivo.54 Two studies55,56 investigated the effects of SS analogs in human corticotroph adenoma tissues; a superior ACTH inhibition by pasireotide as compared with octreotide55 and a dissociation in some adenomas between the antisecretory and antiproliferative effects of pasireotide56 were reported similar to what is observed in acromegaly.57,58

Efficacy in clinical studies

sst2 Binding (binds) of in superior associated with adenoma, acromegaly, acth-secreting pituitary adenoma and somatostatin
3) Confidence 0.17 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.37 Pain Relevance 0.64
-actin mRNA expression in each individual sample were expressed in arbitrary units as a ratio of sst2 over ?
sst2 Binding (ratio) of
4) Confidence 0.07 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC151791 Disease Relevance 0.07 Pain Relevance 0
Recently published data point to the involvement of SRIF/sst2 receptor interaction in the control of proliferation of Sertoli cells [8] and spermatogonia [4].
sst2 Binding (interaction) of in Sertoli cells associated with somatostatin
5) Confidence 0.07 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC151791 Disease Relevance 0 Pain Relevance 0.43
Few commonly available ligands (e.g. octreotide, MK 678 and RC 160) distinguish sst2/sst3/sst5- from sst1/sst4-receptors since they bind to sst2/sst3/sst5 subfamily with subnanomolar affinity and are 1000-fold less efficient on sst1/sst4 subfamily of receptors.
sst2 Binding (bind) of
6) Confidence 0.07 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC151791 Disease Relevance 0 Pain Relevance 0.21
Few commonly available ligands (e.g. octreotide, MK 678 and RC 160) distinguish sst2/sst3/sst5- from sst1/sst4-receptors since they bind to sst2/sst3/sst5 subfamily with subnanomolar affinity and are 1000-fold less efficient on sst1/sst4 subfamily of receptors.
sst2 Binding (bind) of
7) Confidence 0.07 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC151791 Disease Relevance 0 Pain Relevance 0.21
Amplification for sst2 and ?
sst2 Binding (Amplification) of
8) Confidence 0.06 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC151791 Disease Relevance 0 Pain Relevance 0
Five subtypes (sst1–5) have been described, and the currently available somatostatin analogues bind with high affinity to sst2 and sst5.
sst2 Binding (bind) of associated with somatostatin
9) Confidence 0.04 Published 2008 Journal Clinical Endocrinology Section Body Doc Link PMC2610402 Disease Relevance 0.17 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox